2. Immunology/Inflammation
  3. Interleukin Related
  4. Tocilizumab

Tocilizumab  (Synonyms: Anti-Human IL6R, Humanized Antibody; RG-1569; rhPM-1)

Cat. No.: HY-P9917 Purity: 99.47%
COA
SDS
Technical Support

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).

For research use only. We do not sell to patients.

CAS No. : 375823-41-9

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 42 publication(s) in Google Scholar

Tocilizumab Featured Recommendations:

Tocilizumab Related Antibodies

Top Publications Citing Use of Products

42 Publications Citing Use of MCE Tocilizumab

Cell Imaging/Staining
ELISA
IF
RT-PCR

    Tocilizumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373.  [Abstract]

    Representative images of fibrosis-induced spheroids subjected to microfluidic deformation analysis, comparing untreated control, antifibrotic drug NTD, and anti-interleukin drugs TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.

    Tocilizumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373.  [Abstract]

    IL-6 concentrations of fibrosis-induced spheroids measured in culture supernatants following drug treatments. Tocilizumab (TCZ, 5 μg/mL, 1 d) were added.

    Tocilizumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373.  [Abstract]

    TGF-β concentrations of fibrosis-induced spheroids measured in culture supernatants following drug treatments. Tocilizumab (TCZ, 5 μg/mL, 1 d) were added.

    Tocilizumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373.  [Abstract]

    Confocal fluorescence images showing the expression of collagen-1 and α-SMA in spheroids treated with NTD, TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.

    Tocilizumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373.  [Abstract]

    Relative mRNA expression level of α-SMA in spheroids treated with NTD and TCZ, normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression (n = 3). Tocilizumab (TCZ, 5 μg/mL, 1 d) were added.

    View All Interleukin Related Isoform Specific Products:

    View All Isoforms
    IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target[1][2]

    IL-6Ra

     

    In Vitro

    Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Tocilizumab Related Antibodies

    Cell Proliferation Assay[2]

    Cell Line: Human-derived HARA-B cells
    Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL
    Incubation Time: 24 hours, 48 hours
    Result: Inhibited the IL-6R expressed on human-derived HARA-B cells.

    Cell Cytotoxicity Assay[1]

    Cell Line: Ba/F3-gp130-IL-6R cells
    Concentration: 0.001–10000 μg/ml
    Incubation Time: 2 days
    Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation.

    Western Blot Analysis[3]

    Cell Line: SAS cells
    Concentration: 1 μM
    Incubation Time: 6 hours
    Result: Reduced the phosphorylation of STAT3.

    RT-PCR[3]

    Cell Line: SAS cells
    Concentration: 1-5 μM
    Incubation Time: 24 hours
    Result: Reduced VEGF mRNA expression.
    In Vivo

    Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
    Dosage: 1.0 mg/100 μL
    Administration: Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
    Result: Led the volume of each metastatic focus significantly smaller.
    Animal Model: SCID mice with SAS cells[3]
    Dosage: 100 μg/mL
    Administration: Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
    Result: Suppressed the growth of advanced tumors.
    Clinical Trial
    Gene ID

    3570  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145.2 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Tocilizumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Immobilized Human IL-6Ra/CD126, His Tag can bind Tocilizumab. The EC50 for this effect is 30.32 ng/mL.
    • Flow cytometry analysis of IL-6R expression U937 cells labelling IL-6R with Tocilizumab at 10nM (Red), 20ng/mL of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) were added to block the binding of Fc of antibody to cells respectively. Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
    Purity & Documentation

    Purity: 99.67%

    SDS (252 KB)

    COA (232 KB) SDS-PAGE (85 KB) SEC-HPLC (97 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Tocilizumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Tocilizumab375823-41-9Anti-Human IL6R, Humanized Antibody RG-1569 rhPM-1RG1569RG 1569RG-1569rhPM1rhPM 1rhPM-1Interleukin RelatedILantibodyIL-6RNeutralizingrheumatoidarthritisSARS-CoV-2coronavirus diseaserespiratory failuredyspnoeaCOVID-19Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tocilizumab
    Cat. No.:
    HY-P9917
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.